Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Effector rises on positive pre-clinical data on cancer drug

** Shares of cancer drug developer Effector Therapeutics
 EFTR.O  up ~7% at $7.83 premarket
    ** Co publishes pre-clinical data highlighting the
anti-tumor potential of its drug candidate, zotatifin
 urn:newsml:reuters.com:*:nGNX2JXLGg
    ** Data shows zotatifin suppressed the expression of certain
proteins that are mutated and over-expressed in many cancers
    ** Research also shows combinations of zotatifin with other
cancerous protein inhibitors led to enhanced anti-tumor activity
- EFTR 
    ** Up to Tuesday's close, stock had fallen 26.23% since its
debut on March 1 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news